Jefferies Group Downgrades Salix Pharmaceuticals to Neutral (SLXP)
Several other analysts have also recently commented on the stock. Analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Salix Pharmaceuticals in a research note on Friday. They now have a $147.00 price target on the stock, down previously from $160.00. Separately, analysts at Mizuho cut their price target on shares of Salix Pharmaceuticals from $205.00 to $195.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald upgraded shares of Salix Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. They now have a $157.00 price target on the stock, up previously from $121.00. One analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. Salix Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $134.15.
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) traded down 3.94% during mid-day trading on Friday, hitting $128.29. The stock had a trading volume of 4,065,787 shares. Salix Pharmaceuticals has a 1-year low of $64.93 and a 1-year high of $141.81. The stock’s 50-day moving average is $131.3 and its 200-day moving average is $113.0. The company has a market cap of $8.135 billion and a P/E ratio of 113.47.
Salix Pharmaceuticals (NASDAQ:SLXP) last announced its earnings results on Thursday, August 7th. The company reported $1.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by $0.10. The company had revenue of $382.00 million for the quarter, compared to the consensus estimate of $397.06 million. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was up 62.3% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $6.53 earnings per share for the current fiscal year.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.